JP2002540127A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002540127A5 JP2002540127A5 JP2000607588A JP2000607588A JP2002540127A5 JP 2002540127 A5 JP2002540127 A5 JP 2002540127A5 JP 2000607588 A JP2000607588 A JP 2000607588A JP 2000607588 A JP2000607588 A JP 2000607588A JP 2002540127 A5 JP2002540127 A5 JP 2002540127A5
- Authority
- JP
- Japan
- Prior art keywords
- cholesterol
- level
- lipg
- apolipoprotein
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- 102100031375 Endothelial lipase Human genes 0.000 description 25
- 101000941275 Homo sapiens Endothelial lipase Proteins 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 108010010234 HDL Lipoproteins Proteins 0.000 description 15
- 102000015779 HDL Lipoproteins Human genes 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 15
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 14
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 14
- 238000006911 enzymatic reaction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000008214 LDL Cholesterol Methods 0.000 description 8
- 108010069201 VLDL Cholesterol Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/277,401 US7008776B1 (en) | 1996-12-06 | 1999-03-26 | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
| US09/277,401 | 1999-03-26 | ||
| PCT/US2000/007870 WO2000057837A2 (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002540127A JP2002540127A (ja) | 2002-11-26 |
| JP2002540127A5 true JP2002540127A5 (enExample) | 2008-06-26 |
Family
ID=23060703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000607588A Pending JP2002540127A (ja) | 1999-03-26 | 2000-03-24 | コレステロールのレベルをもたらすための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1171078A4 (enExample) |
| JP (1) | JP2002540127A (enExample) |
| KR (2) | KR100887164B1 (enExample) |
| AU (1) | AU776684B2 (enExample) |
| BR (1) | BR0009333A (enExample) |
| CA (1) | CA2363486C (enExample) |
| HK (1) | HK1043309A1 (enExample) |
| IL (2) | IL145526A0 (enExample) |
| MX (1) | MXPA01009727A (enExample) |
| NO (2) | NO331779B1 (enExample) |
| NZ (2) | NZ514350A (enExample) |
| WO (1) | WO2000057837A2 (enExample) |
| ZA (1) | ZA200107598B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
| EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
| EP2370582B1 (en) | 2008-12-04 | 2017-05-10 | CuRNA, Inc. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| CN102317458B (zh) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | 通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗 |
| PT2396038E (pt) | 2009-02-12 | 2016-02-19 | Curna Inc | Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf |
| CA2755409C (en) | 2009-03-16 | 2019-04-30 | Joseph Collard | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
| JP5904935B2 (ja) | 2009-03-17 | 2016-04-20 | クルナ・インコーポレーテッド | デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療 |
| JP6250930B2 (ja) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療 |
| EP2427553A4 (en) | 2009-05-06 | 2012-11-07 | Opko Curna Llc | TREATMENT OF LIPID TRANSPORT AND METABOLISM-RELATED DISEASES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A LIPID TRANSPORT AND METABOLIC TREATMENT |
| ES2664590T3 (es) | 2009-05-18 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con factores de reprogramación por inhibición del tránscrito antisentido natural a un factor de reprogramación |
| CN102549158B (zh) | 2009-05-22 | 2017-09-26 | 库尔纳公司 | 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病 |
| CN102695797B (zh) | 2009-06-16 | 2018-05-25 | 库尔纳公司 | 通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病 |
| ES2629339T3 (es) | 2009-06-16 | 2017-08-08 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1 |
| ES2618894T3 (es) | 2009-06-24 | 2017-06-22 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2 |
| KR101807324B1 (ko) | 2009-06-26 | 2017-12-08 | 큐알엔에이, 인크. | 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료 |
| WO2011011700A2 (en) | 2009-07-24 | 2011-01-27 | Curna, Inc. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| WO2011019815A2 (en) | 2009-08-11 | 2011-02-17 | Curna, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
| US8791087B2 (en) | 2009-08-21 | 2014-07-29 | Curna, Inc. | Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP |
| CN102482671B (zh) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病 |
| CN102791861B (zh) | 2009-09-25 | 2018-08-07 | 库尔纳公司 | 通过调节聚丝蛋白(flg)的表达和活性而治疗flg相关疾病 |
| KR101823702B1 (ko) | 2009-12-16 | 2018-01-30 | 큐알엔에이, 인크. | 막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료 |
| KR101793753B1 (ko) | 2009-12-23 | 2017-11-03 | 큐알엔에이, 인크. | 커플링방지 단백질 ２(ｕｃｐ２)에 대한 천연 안티센스 전사체의 저해에 의한 ｕｃｐ２ 관련 질환의 치료 |
| DK2516648T3 (en) | 2009-12-23 | 2018-02-12 | Curna Inc | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF |
| ES2657452T3 (es) | 2009-12-29 | 2018-03-05 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor respiratorio nuclear 1 (NRF1) mediante inhibición de transcrito antisentido natural a NRF1 |
| CN102770540B (zh) | 2009-12-29 | 2017-06-23 | 库尔纳公司 | 通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病 |
| RU2016115782A (ru) | 2009-12-31 | 2018-11-28 | Курна, Инк. | Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3) |
| DK2521784T3 (en) | 2010-01-04 | 2018-03-12 | Curna Inc | TREATMENT OF INTERFERON REGULATORY FACTOR 8- (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IRF8 |
| CA2786535C (en) | 2010-01-11 | 2019-03-26 | Curna, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
| US8946182B2 (en) | 2010-01-25 | 2015-02-03 | Curna, Inc. | Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1 |
| JP5976548B2 (ja) | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー，インコーポレイテッド | Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療 |
| TWI600759B (zh) | 2010-04-02 | 2017-10-01 | 可娜公司 | 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病 |
| US9044494B2 (en) | 2010-04-09 | 2015-06-02 | Curna, Inc. | Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21 |
| US9089588B2 (en) | 2010-05-03 | 2015-07-28 | Curna, Inc. | Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT) |
| TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病 |
| EP2576784B1 (en) | 2010-05-26 | 2017-11-15 | CuRNA, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
| EP3299464B1 (en) | 2010-05-26 | 2019-10-02 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
| JP6023705B2 (ja) | 2010-06-23 | 2016-11-09 | カッパーアールエヌエー，インコーポレイテッド | ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療 |
| CN103068982B (zh) | 2010-07-14 | 2017-06-09 | 库尔纳公司 | 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病 |
| WO2012054723A2 (en) | 2010-10-22 | 2012-04-26 | Opko Curna Llc | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
| WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
| EP2643463B1 (en) | 2010-11-23 | 2017-09-27 | CuRNA, Inc. | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| EP2718439B1 (en) | 2011-06-09 | 2017-08-09 | CuRNA, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
| EP2753317B1 (en) | 2011-09-06 | 2020-02-26 | CuRNA, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
| HK1210211A1 (en) | 2012-03-15 | 2016-04-15 | 科纳公司 | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| CN102628060A (zh) * | 2012-03-22 | 2012-08-08 | 北京济福霖生物技术有限公司 | 一种低脂奶的生产方法 |
| US9695462B2 (en) | 2012-11-05 | 2017-07-04 | Shionogi & Co., Ltd. | Method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity and a method for screening an inhibitor of EL activity |
| MY166357A (en) * | 2013-03-14 | 2018-06-25 | Shionogi & Co | Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase |
| TWI688575B (zh) | 2014-09-11 | 2020-03-21 | 日商塩野義製藥股份有限公司 | 阻礙血管內皮脂酶之酵素活性的人類化單株抗體 |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| US20240277861A1 (en) * | 2021-07-26 | 2024-08-22 | Purotech Bio, Inc. | Anti-hepatitis b virus agent targeting host factor lipg |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08507203A (ja) * | 1992-12-04 | 1996-08-06 | イノーバー ラボラトリーズ，インコーポレイテッド | 調節可能な核酸治療およびそれらの使用方法 |
| DE69732789T2 (de) * | 1996-12-06 | 2005-08-11 | Aventis Pharmaceuticals Inc. | Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden |
| WO1999032611A1 (en) * | 1997-12-19 | 1999-07-01 | Progenitor, Inc. | A lipase expressed in endothelial cells and methods for its use |
-
2000
- 2000-03-24 EP EP00918362A patent/EP1171078A4/en not_active Ceased
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/ko not_active Expired - Fee Related
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/xx not_active IP Right Cessation
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/ko not_active Ceased
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/pt not_active Application Discontinuation
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/en not_active Ceased
- 2000-03-24 HK HK02104818.0A patent/HK1043309A1/zh unknown
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/es active IP Right Grant
- 2000-03-24 IL IL14552600A patent/IL145526A0/xx unknown
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/ja active Pending
- 2000-03-24 CA CA2363486A patent/CA2363486C/en not_active Expired - Fee Related
-
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/xx unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/no not_active IP Right Cessation
-
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002540127A5 (enExample) | ||
| CA2363486A1 (en) | Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol | |
| Mackness et al. | Paraoxonase activity in two healthy populations with differing rates of coronary heart disease | |
| Kim et al. | Association between osteoprotegerin (OPG), receptor activator of nuclear factor-κB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women | |
| Bauer et al. | Risk for fracture in women with low serum levels of thyroid-stimulating hormone | |
| Satoh et al. | Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer | |
| Argraves et al. | The atherogenic lipoprotein Lp (a) is internalized and degraded in a process mediated by the VLDL receptor. | |
| Marzetti et al. | Effects of short-term GH supplementation and treadmill exercise training on physical performance and skeletal muscle apoptosis in old rats | |
| Huang et al. | The mitochondrial cardiolipin remodeling enzyme lysocardiolipin acyltransferase is a novel target in pulmonary fibrosis | |
| Ojala et al. | Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non‐familial hypercholesterolaemia | |
| WO2014059178A1 (en) | Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis | |
| Zhao et al. | Anti-monocyte chemoattractant protein 1 gene therapy attenuates experimental chronic pancreatitis induced by dibutyltin dichloride in rats | |
| Mera et al. | Clinicopathologic study on prognostic markers in IgA nephropathy | |
| Saha et al. | DNA polymorphisms of the apolipoprotein B gene in Chinese coronary artery disease patients | |
| Moffett et al. | Association of the G‐174C variant in the interleukin‐6 promoter region with bone loss and fracture risk in older women | |
| De Andrade et al. | Protein nitration, metabolites of reactive nitrogen species, and inflammation in lung allografts | |
| AU2019270404B2 (en) | Blood biomarkers of stroke | |
| Guzmán et al. | Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease | |
| Srinivasan et al. | Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community: The Bogalusa Heart Study | |
| Saitoh et al. | Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands | |
| Yoshikawa et al. | Neutrophil gelatinase‐associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases | |
| WO2012107580A1 (en) | In vitro diagnosis method for predicting a predisposition to cardiomyopathy | |
| Marcovina et al. | Lipoprotein (a) and coronary heart disease risk | |
| JP2003524017A5 (enExample) | ||
| Andric et al. | Human cytomegalovirus is present in odontogenic cysts |